Thomas Clozel

🔍 Join our facilitator Alexander Ivliev at his Roundtable Discussion at the AI in Drug Discovery Xchange 2024, Boston! 🧪 📚 Dive deep into the realm of target discovery with our esteemed facilitator, Alexander Ivliev, Director of Computational Biology at Ikena Oncology. In this interactive roundtable discussion, we will brainstorm the vital components essential for a robust target discovery engine and unravel the mystery of how to integrate them effectively. ⌚ Time: 15:40 – 16:40 📅 Date: 20th June 2024 📍 Location: Woburn Hilton Hotel, 2 Forbes Road, Woburn, US 🪧 Join us today & claim your COMPLIMENTARY pass today! 🪧 https://bit.ly/43qUJXC ✨ Session Highlights ✨ 🔵 The balance between in-house experimentation and leveraging public resources in target identification. 🔵 Exploring the most informative experimental approaches and data types. 🔵 Navigating approaches tailored for efficacy versus safety. 🔵 Strategies for managing the trade-off between target novelty and confidence level. 🔵 Piecing together the components into a cohesive framework. 🗣️ Alexander brings a wealth of expertise to the table, with a master’s and PhD in Bioinformatics and over a decade of experience in the field. Having spearheaded bioinformatics initiatives at Clarivate Analytics, supporting diverse clients in pharmaceutical and biotech sectors, Alexander now leads the computational biology domain at Ikena Oncology. His role is pivotal in accelerating the development of small-molecule inhibitors for cancer treatment. Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 * Agenda subject to change #TargetDiscovery #DrugDiscovery #Bioinformatics #AIinHealthcare #AIinDrugDiscovery #InnovationInMedicine #RoundtableDiscussion #Biotech #Pharmaceuticals #DataDrivenDiscovery #ExperimentalApproaches #EfficacyVsSafety #NovelTargets #ConfidenceInDiscovery #InHouseExperimentation #PublicResources #CollaborativeScience #ScientificAdvancements #BiomedicalResearch #PrecisionMedicine #FutureOfMedicine #StrategicThinking #BioinformaticsInsights #hubXchange #Roundtable #FreePass #RegisterNow #ComplimentaryPass

5

📊 𝑬𝑳𝑨𝑽𝑨𝒀 𝐔𝐧𝐯𝐞𝐢𝐥𝐬 2024 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭: 𝘋𝘳𝘪𝘷𝘪𝘯𝘨 𝘐𝘯𝘯𝘰𝘷𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘈𝘥𝘷𝘢𝘯𝘤𝘦𝘮𝘦𝘯𝘵𝘴 𝘪𝘯 𝘊𝘢𝘯𝘤𝘦𝘳 𝘛𝘳𝘦𝘢𝘵𝘮𝘦𝘯𝘵 Archo Advocacy, LLC, proudly presents this comprehensive report highlights the latest trends, innovations, and top contributors in oncology, emphasizing advancements in cancer treatment from patient perspectives. Key Areas Include ⬇ ☑ Partnership Support ☑ Policy Activities ☑ Corporate Reputation ☑ Health Equity & Social Determinants of Health. Discover top performers like The Janssen Pharmaceutical Companies of Johnson & Johnson, Pfizer, and Merck, and gain strategic insights essential for driving success in the oncology landscape. 📈 #OncologyResearch #CancerTreatment #HealthcareInnovation #PatientAdvocacy #HealthcareInnovation #Pharma #Biotech

1

International Collaborative Study! #CollaborativeResearch We're elated to announce the remarkable findings from our collaborative latest study, "Molecular insights from comprehensive genomic profiling data in advanced metastatic colorectal cancer in South Asian populations: A retrospective observational study". Highlighting the benefit of precision medicine by giving the cancer patient best chance at fighting cancer. The study was published in the esteemed journal CRST, highlighting the significant insights into metastatic colorectal cancer in a Southeast Asian cohort. The research revealed that comprehensive genomic profiling (CGP) identified clinically actionable variants in 78.6% of patients. While 30.8% were eligible for targeted therapies, 29.5% harbored variants linked to therapeutic resistance. There were key mutations in APC, TP53, and KRAS, with significant genomic alterations in PIK3CA, SMAD4, BRAF, and others. Biomarker testing showed that 15.8% had a high tumor mutation burden, 14% had high microsatellite instability, and 26.8% were PD-L1 positive. CGP proves advantageous for improving patient outcomes by identifying therapy-eligible subsets. Find the full study: https://lnkd.in/gWUcynnm We are immensely grateful for the contributions made by each member of the research team. The success of this study in advancing patient care and outcomes is a testament to your unwavering dedication and exceptional contributions. Collaborating with the International Principal Investigators has been a true honor. A huge congratulations to everyone on the team. Nusrath Fathima, Kritika Verma, Paridhy Vanniya Subramanyam, Nilesh Mukherjee, Nishtha Tanwar, Sharanya J, Saranya Rangan V, Shreya Mahanti, Prabir Saha, Vyomesh Javle, Satya Prakash Khuntia, Harshi Santani, Ashwini Prakash, Sreekanth Reddy P., Pooja Gowda, Linu Varghese, Dr. Adwaita Gore, Dr. Anjana Sainani, Dr. Ashay Karpe Dr. Avinash CB, Dr. Bharat Patodiya, Dr. Ghanashyam Biswas, Dr. Nilesh Lokeshwar, Dr. rohit ranade, Dr. Necy Juat, Federico Miguel R, Dr. Annielyn Beryl, Dr. Catherine Teh, Surgeon, Dr. V. P. Gangadharan, Dr. Amit Jain, Dr. Mostafa A. Sumon, Dr.Ramakant Deshpande, Dr.Vijay Patil, Dr. Vishwanath Sathyanarayanan, Dr. A.V.S. Suresh, Dr. Bhuvan Chugh, Dr. Abhinav Zawar, Dr. Ajay Gupta, Dr. Akshay Shah, Ankur Punia, Dr. Kamruzumman Rumman, Dr. Mangesh Kamath, Dr.Saadvik Raghuram Y, Dr. Sai Vivek, Dr Sudip Shrestha, Dr. Vineet G. Gupta, Raja Pramanik, Dr. Bharat Bhosale, Dr. ARUN WARRIER, Dr. P. Guhan, Dr. Viraj Lavingia, Dr. Vinu Sarathy, Dr. Sourav Mishra, Dr. Raja Thirumalairaj, Dr Sandeep Nayak, Kshitij Rishi, Hitesh Goswami, Dr. Vidya H Veldore #Research #Cancer #Oncology #ColorectalCancer #CGP #TargetedTherapy #CRSTonline #4baseCare #TogetherWeBeatCancer

63

2 Comments

It's been a wave of important tech developments in the pharma/biotech space. We have summarized some of the most important tech+bio highlights to watch in the latest newsletter (link in the comments). Also, in this newsletter: The Rise of AI Foundation Models in Biotech: A New Paradigm. Read the newsletter following the link below 👇 #biopharmatrend #techbio #science

10

Intron Health has raised $1.6M in a pre-seed funding round. The round was led by Microtraction, with participation from @Plug and Play Ventures, Jaza Rift Ventures, Octopus Ventures, Africa Health Ventures, Openseed VC, Pi Campus, Alumni Angel, and Baker Bridge Capital. The investment also saw contributions from angel investors from global companies, including Google, CLEAR Global, NYU, and Optum. Read More: https://lnkd.in/dRwehhFd Launched in 2020 to digitise healthcare, Intron Founder, Tobi Olatunji MD quickly recognised data entry was a massive bottleneck to electronic medical record adoption. Heavy patient traffic meant thousands of keystrokes per day, increasing documentation time and patient wait time, with doctors sometimes spending over six hours a day on paperwork. The significant additional workload made digitization impractical for already overworked clinicians. To combat these inefficiencies, Intron developed Africa’s first clinical speech recognition platform, which boasts up to 92% accuracy rate on medical terminology with heavy accents. This platform helps doctors across #Nigeria, #Ghana, #Kenya, #SouthAfrica and most recently #Uganda complete documentation seven times faster, significantly accelerating the adoption of Electronic Health Records (EHR) and reducing the administrative burden. Plug and Play Tech Center, Baker Donelson, New York University, Alexander Tran, Yele Bademosi, Bayo Okusanya,Florence Yula (FMVA), Jennifer Ifeatu Orisakwe #mededgemea #intronhealth #aihealthtech #GlobalHealth #HealthInnovation #healthtech #medicalAI #HealthcareRevolution #techforgood #FutureOfHealthcare

31

1 Comment

Recent Funding: New #AI drug discovery powerhouse Xaira Therapeutics (San Francisco) rises with $1 billion in funding - the largest initial funding commitment in ARCH history. Incubated by ARCH Venture Partners and Foresite Labs with none other than Marc Tessier-Lavigne, Ph.D., former CSO at Genentech, at the helm. The company was co-founded by David Baker, Ph.D., professor of biochemistry and director of the Institute for Protein Design at the University of Washington. Xaira will combine machine learning, data generation and therapeutic product development to build a platform for #drugdiscovery. Endeavor BioMedicines (San Diego) pulls in $132M to back #cancer, lung disease drugs. The oversubscribed series C stretches the company's cash runway through 2026. Money will be channeled into lead asset ENV-101, which is designed to block a cellular wound-healing pathway known as Hedgehog. Phase 2a data set to be presented at the American Thoracic Society annual meeting show that no patients treated with ENV-101 had signs of disease progression, compared to two given placebo. Norwest Venture Partners (Menlo Park) announces $3 Billion global fund to partner with the next generation of enduring companies. Norwest expanded the focus of its healthcare practice over the last two years by adding #biotech. The most recent biotech company investments include Engrail Therapeutics and Ray Therapeutics, Inc. Recent Layoffs: Bristol Myers Squibb plans to cut costs by $1.5 billion by the end of 2025 in a massive restructure that includes laying off about 2,200 employees. The company is shuttering its Cancer Immunology & Cell Therapy Thematic Research Center in Redwood City, CA. M&A, Deals, Partnerships: Incyte announced that it is buying Escient Pharmaceuticals for $750 million to gain control of a pipeline led by clinical-phase treatments of atopic #dermatitis and other skin conditions. Escient’s lead asset is an antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2), a receptor that is expressed on mast cells. The small molecule, EP262, is in Phase Ib/II trials in those three conditions and clinical proof-of-concept data are due early in 2025. Cidara Therapeutics (San Diego) reacquires global development and commercial rights to CD388 and announces private placement financing of $240 Million. The financing was led by RA Capital Management to fund Phase 2b clinical trial of CD388, which is active against all strains of influenza A and B, and being developed for pre-exposure prophylactic treatment. Regeneron expands in gene editing with $100 million #CRISPR drug developer Mammoth Biosciences deal (Brisbane, CA). Through their collaboration, the companies plan to develop in vivo gene therapies that combine Regeneron’s viral vector technology with Mammoth’s #DNA editing platforms, which are designed to be more compact than the industry standard.

15

While mRNA modification has significantly mitigated inflammation and toxicity in RNA therapies, leading to successful market entries, the same success has not been fully mirrored in lipid-based delivery systems. The toxicity and inflammatory responses associated with these delivery vehicles remain critical hurdles, as evidenced by numerous clinical trial failures involving LNPs and other advanced delivery systems. At Orion Therapeutics, our cutting-edge lipopeptide delivery platform addresses these challenges by enhancing the therapeutic index and reducing toxicity, offering a robust solution for the most challenging hurdles in genetic medicine - The Issue of Delivery. Recognizing the potential of our platform to address a wide range of therapeutic areas, we are actively seeking opportunities to out-license our technology. This strategic approach allows us to collaborate with partners aiming to harness the power of RNA therapies in their own pipelines, expanding the impact of our innovations across the biotech landscape and contributing to the advancement of genetic medicine. Join us at the MassBio Align Summit to explore how our technology is setting new benchmarks; we will be presenting at 10:50 AM tomorrow in the East Tower room. #AlignSummit24 #AlignSummit #AIDrugDiscovery #LNP #RNA

13

🔬 Join us at Oligonucleotide Therapeutics Xchange, Boston 2024, on June 21st, for a dynamic roundtable session on "Emerging Opportunities for Liver-Targeting and Extrahepatic Areas" within the Oligonucleotide Discovery track. 🔬 🌟 We're thrilled to announce Lakshmi Bhagat, Associate Scientific Director at Luye Pharma Group, as the facilitator for this insightful discussion. Lakshmi brings a wealth of expertise and leadership from her current role as Associate Director at GeneLeap Biotechnology. 🎓 Lakshmi holds a PhD from the University of Delhi, India, and has honed her skills through postdoctoral training at Massey University, New Zealand, and Harvard Medical School. With over 20 years of experience in the drug development industry, Lakshmi specializes in nucleic acid therapeutics, including innate immune receptor agonists and antagonists, antisense, and siRNA. 💡 Notably, Lakshmi played a pivotal role in the development of Idera Pharmaceuticals's TLR9 agonist, Tilsotolimod, from discovery to Phase 3 clinical trial. Her contributions extend beyond the lab, with co-inventorship of 33 US patents and authorship of 50+ peer-reviewed publications. 🚀 Don't miss the opportunity to gain insights from Lakshmi Bhagat and other industry leaders at Oligonucleotide Therapeutics Xchange 2024. Register now and be part of shaping the future of oligonucleotide therapeutics! 🔒 SECURE YOUR COMPLIMENTARY PASS TODAY! 🔒 https://bit.ly/3wYHLnQ 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 * Agenda subject to change. #OligonucleotideTherapeutics #DrugDiscovery #Biotech #Pharma #Innovation #DrugDevelopment #Science #Research #Oligonucleotides #Therapeutics #Healthcare #LifeSciences #Leadership #Roundtable #BostonEvents #Networking #ScientificCommunity #ClinicalTrials #MedicalResearch #Genetics #hubXchange #FreePass #RegisterNow #ComplimentaryPass

40

“To us, this is what we mean by methodological transparency. And it does not equate explainability because inherently, for a lot of data-driven technology, explainability may be very difficult to achieve.” Dr. Tala Fakhouri, Associate Director for Data Science and Artificial Intelligence Policy, FDA speaks to how the FDA is thinking about transparency in AI models and questions to consider in submissions. Listen to the full discussion on ACRO’s Good Clinical Podcast:

64

3 Comments

This edition of the CCO Paper of the Week is brought to you by Nathan Lee (now a post-doc with Roland Schwarz), Kamran Kaveh, and Ivana Bozic who recently contributed a review article on clonal interactions in cancer. In particular, they discuss mathematical and computational models for representing clonal interactions in experimental systems. Consider checking it out: https://lnkd.in/gAPQ7G_x

6

𝐎𝐛𝐞𝐬𝐢𝐭𝐲 𝐆𝐋𝐏-𝐈 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞 🔥 The landscape of GLP-1 therapies is rapidly expanding, with potential impacts now reaching into cardiovascular risk, sleep apnoea, and liver disease. Among startups, Viking Therapeutics, Inc., and Altimmune, Inc. have garnered attention for their promising GLP-1 candidates focused on weight loss. Viking's VK2735 showed significant weight loss of up to 13% in a Phase 2 trial over 13 weeks, without plateauing, suggesting potential for further reduction with longer treatment. 👉 Novo's recent FDA approval for Wegovy, extending its use to cardiovascular risk reduction, illustrates the path forward for broadening therapeutic applications. Full credit to Arjun Murphy and MavenBio.Io - great work. #obesity #biotech #biopharma

92

1 Comment

🚀 Missed our live webinar on Mast Cells? It’s not too late! 🚀 Join Prof. Marcus Maurer as he dives deep into the intriguing world of #mastcells, discussing their critical roles in both safeguarding health and contributing to #inflammatory diseases. Don’t miss this opportunity to access insights on how these vital cells can both defend against and exacerbate #health conditions. What You'll Discover: ➡️ The dual nature of mast cells in immune responses. ➡️ Advanced methodologies for studying mast cell activation and behavior. ➡️ Innovative therapeutic strategies aimed at modulating mast cell activity to combat inflammation. 🌐 Watch the replay now and empower your understanding of these pivotal immune players. Perfect for professionals in #immunology, #dermatology, and related fields seeking to enhance their knowledge and apply it in clinical or #research settings. 🔗 https://bit.ly/3vTzzoI

5

Big News in AI-Driven Healthcare! 🔥 M42 Health, the healthcare subsidiary of G42, just launched two groundbreaking versions of Med42 LLM - Med42 v2 8B and Med42 v2 70B! These models, hosted on Hugging Face, are set to revolutionize medical expertise access and cater to healthcare professionals' needs. Built on Meta's LLaMA-3 architecture, the Med42 v2 models deliver unparalleled medical insights with advanced question answering, patient record summarization, and diagnostic support. Last year's Med42 70B saw over 8200 downloads, and this year's models are already surpassing benchmarks set by Meta LLaMA-3 and GPT-40! Curious about the full story and the impressive Elo Ratings? Read the complete article to know more. Link in the comments below 👇

50

1 Comment

Weekly Tech+Bio Highlights: • Building Foundation Models for Cancer Biology: NOETIK is developing self-supervised world models that learn cancer biology from primary data to discover new therapeutic insights, co-founded by Ron Alfa, MD, PhD. • Meet nach0: a New General Purpose LLM for Chemical and Biomedical Applications: Insilico Medicine and NVIDIA introduced nach0, a large language model for biological and chemical tasks, detailed in the Chemical Science Journal. Alex Zhavoronkov, CEO of Insilico Medicine, highlights the model's capabilities in integrating diverse datasets for biological and chemical applications. • Owkin, co-founded by Thomas Clozel Unveils AI-Driven Oncology and Immunology Pipeline: Owkin has unveiled an AI-driven pipeline, featuring OKN4395, a dual EP2/4 antagonist, set for Phase 1 trials in 2025. • Novel Cell Analytics Technology: Cytomos will present its advanced cell analytics technology, Celledonia™, at ISCT 2024, enhancing cell and gene therapy processes. • Quantum Computing in Biopharma: - Key companies and initiatives; - Quantum advantage in biopharma; - Challenges and future outlook. • New Discovery Potentially to Re-write Biology Textbooks: Researchers have discovered a unique bacterial enzyme that creates new genes by reading RNA templates and converting them into DNA, challenging the traditional understanding of genetic information flow. For a more detailed overview and more, check out the full article: https://lnkd.in/dxPJ5MCe

23

#LanternPharma announced a strategic AI-driven collaboration with #OregonTherapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications. https://shorturl.at/alnoZ #TechNews #StayInformed #StayAhead #dailydose #followus #staytuned #stayconnected #technews #technology #trending #trendingnow #trendingnews #explore #explorepage #techdogs

5

Nabla Bio (YC S20) has raised $26 million in Series A funding to use AI to design antibodies for intractable diseases. AI is quickly becoming one of the most transformative technologies available, capable of designing drugs with atomic precision. However, human biology's complexity exceeds both our current understanding and the training scope of AI — so it is essential to also develop methods for empirically measuring drug properties relevant to humans on a large scale. Founded by Surge Biswas and Frances Anastassacos, Nabla combines AI-guided design with wet-lab measurements to develop drugs that are not only safer and more effective but also easier to manufacture. This approach holds the promise of tackling diseases that remain beyond our reach today. Their mission is to enable pharmaceutical and biotech companies to bring more antibody therapies to patients. Using AI and massively parallel experimentation, Nabla designs antibodies that precisely bind the disease target at the right location, while minimizing manufacturability and toxicity risks. Congrats to the team on the Series A!

228

10 Comments